OssiFi Therapeutics

Executive Summary

OssiFi Therapeutics is a Boston-based bone biology company pioneering sclerostin-targeting therapies for orthopedic and regenerative medicine applications. Founded in 2019, the company addresses significant unmet needs in neurogenic low back pain, fracture repair, and fracture prevention through a unique combination of biologic therapeutics and medical devices. By inhibiting sclerostin, OssiFi aims to enhance bone formation and reduce bone resorption, offering a novel approach to conditions where current treatments are limited. The company's lead program focuses on a locally delivered anti-sclerostin antibody for low back pain associated with vertebral bone defects, potentially providing a non-surgical alternative. OssiFi's dual platform strategy leverages both drug and device expertise to optimize delivery and efficacy, positioning it to capture a substantial market in orthobiologics. Despite being in early stages, the company's innovation and clear unmet need make it an attractive prospect in the regenerative medicine space.

Upcoming Catalysts (preview)

• Q3 2026IND Filing for Lead Anti-Sclerostin Therapy70% success
• Q4 2026Initiation of Phase 1 Clinical Trial for LBP Indication60% success
• Q1 2027Strategic Partnership or Licensing Deal for Fracture Repair Program55% success